$45K
+$45K this year1 filing since 2026 · latest Equity filed
Pahtia Technologies Inc. (Pahtia Technologies) is a precision-oncology company headquartered in South Bend, Indiana that uses next-generation sequencing and artificial intelligence to widen access to cancer genomic profiling in populations under-represented in cancer research. Its Genomic Profile Test analyzes tumor DNA to identify genetic alterations that targeted therapies can act on, listed at $3,000 with a three-to-four-week turnaround, and is delivered through partnerships with local laboratories and hospitals rather than by shipping tissue abroad. The company is also building an AI-driven biomarker discovery platform on genomic data collected in these regions. It runs offices in South Bend and Guatemala City and has hospital partnerships in Panama and Guatemala, with Brazil, South Asia and Africa named as expansion markets.
What sets it apart
Focuses on cancer genomics for populations largely absent from mainstream, European-derived research datasets, pricing profiling well below the $5,000-$10,000 typical cost and sequencing through local labs so patients do not need samples shipped internationally.
A tumor DNA analysis service that uncovers the specific genetic alterations in a patient's tumor which may be targeted by personalized therapies.
